Versant Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
Other funds holding XENE
Versant Capital Management's XENE Position: Q3 2026 in Review
Versant Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q3 2026, closing a stake of 221 shares — an estimated $13.3K sold.
Versant Capital Management first reported a position in XENE in Q2 2026 and held it in 1 quarter. The position peaked at $13.3K in Q2 2026. 288 funds tracked by Wall St. Rank hold XENE as of Q3 2026.
- Versant Capital Management reported no remaining Xenon Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- Versant Capital Management sold 221 Xenon Pharmaceuticals shares in Q3 2026, an estimated $13.3K.
- Versant Capital Management first reported a position in Xenon Pharmaceuticals in Q2 2026 and held it in 1 quarter.
- Versant Capital Management's Xenon Pharmaceuticals position peaked at $13.3K in Q2 2026.
- 288 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.
Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.